vs

Side-by-side financial comparison of BIO-RAD LABORATORIES, INC. (BIO) and BRUKER CORP (BRKR). Click either name above to swap in a different company.

BRUKER CORP is the larger business by last-quarter revenue ($977.2M vs $693.2M, roughly 1.4× BIO-RAD LABORATORIES, INC.). BIO-RAD LABORATORIES, INC. runs the higher net margin — 103.9% vs 2.7%, a 101.2% gap on every dollar of revenue. On growth, BIO-RAD LABORATORIES, INC. posted the faster year-over-year revenue change (3.9% vs -0.2%). BRUKER CORP produced more free cash flow last quarter ($207.2M vs $119.1M). Over the past eight quarters, BRUKER CORP's revenue compounded faster (16.4% CAGR vs 6.5%).

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.

Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts, and is the publicly traded parent company of Bruker Scientific Instruments and Bruker Energy & Supercon Technologies (BEST) divisions.

BIO vs BRKR — Head-to-Head

Bigger by revenue
BRKR
BRKR
1.4× larger
BRKR
$977.2M
$693.2M
BIO
Growing faster (revenue YoY)
BIO
BIO
+4.1% gap
BIO
3.9%
-0.2%
BRKR
Higher net margin
BIO
BIO
101.2% more per $
BIO
103.9%
2.7%
BRKR
More free cash flow
BRKR
BRKR
$88.1M more FCF
BRKR
$207.2M
$119.1M
BIO
Faster 2-yr revenue CAGR
BRKR
BRKR
Annualised
BRKR
16.4%
6.5%
BIO

Income Statement — Q4 2025 vs Q4 2025

Metric
BIO
BIO
BRKR
BRKR
Revenue
$693.2M
$977.2M
Net Profit
$720.0M
$26.0M
Gross Margin
49.8%
46.0%
Operating Margin
-17.2%
7.8%
Net Margin
103.9%
2.7%
Revenue YoY
3.9%
-0.2%
Net Profit YoY
200.6%
89.8%
EPS (diluted)
$26.59
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIO
BIO
BRKR
BRKR
Q4 25
$693.2M
$977.2M
Q3 25
$653.0M
$860.5M
Q2 25
$651.6M
$797.4M
Q1 25
$585.4M
$801.4M
Q4 24
$667.5M
$979.6M
Q3 24
$649.7M
$864.4M
Q2 24
$638.5M
$800.7M
Q1 24
$610.8M
$721.7M
Net Profit
BIO
BIO
BRKR
BRKR
Q4 25
$720.0M
$26.0M
Q3 25
$-341.9M
$-59.6M
Q2 25
$317.8M
$7.6M
Q1 25
$64.0M
$17.4M
Q4 24
$-715.8M
$13.7M
Q3 24
$653.2M
$40.9M
Q2 24
$-2.2B
$7.6M
Q1 24
$383.9M
$50.9M
Gross Margin
BIO
BIO
BRKR
BRKR
Q4 25
49.8%
46.0%
Q3 25
52.6%
44.1%
Q2 25
53.0%
44.9%
Q1 25
52.3%
48.8%
Q4 24
51.2%
50.4%
Q3 24
54.8%
48.4%
Q2 24
55.6%
48.0%
Q1 24
53.4%
48.9%
Operating Margin
BIO
BIO
BRKR
BRKR
Q4 25
-17.2%
7.8%
Q3 25
10.0%
-6.0%
Q2 25
11.8%
1.5%
Q1 25
4.0%
4.0%
Q4 24
8.7%
7.4%
Q3 24
9.9%
7.9%
Q2 24
15.9%
6.0%
Q1 24
7.3%
9.0%
Net Margin
BIO
BIO
BRKR
BRKR
Q4 25
103.9%
2.7%
Q3 25
-52.4%
-6.9%
Q2 25
48.8%
1.0%
Q1 25
10.9%
2.2%
Q4 24
-107.2%
1.4%
Q3 24
100.5%
4.7%
Q2 24
-339.2%
0.9%
Q1 24
62.9%
7.1%
EPS (diluted)
BIO
BIO
BRKR
BRKR
Q4 25
$26.59
$0.10
Q3 25
$-12.70
$-0.41
Q2 25
$11.67
$0.05
Q1 25
$2.29
$0.11
Q4 24
$-25.89
$0.09
Q3 24
$23.34
$0.27
Q2 24
$-76.26
$0.05
Q1 24
$13.45
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIO
BIO
BRKR
BRKR
Cash + ST InvestmentsLiquidity on hand
$1.5B
$298.8M
Total DebtLower is stronger
$1.2B
$1.9B
Stockholders' EquityBook value
$7.5B
$2.5B
Total Assets
$10.6B
$6.2B
Debt / EquityLower = less leverage
0.16×
0.76×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIO
BIO
BRKR
BRKR
Q4 25
$1.5B
$298.8M
Q3 25
$1.4B
$293.1M
Q2 25
$1.4B
$92.0M
Q1 25
$1.7B
$184.2M
Q4 24
$1.7B
$183.4M
Q3 24
$1.6B
$148.1M
Q2 24
$1.6B
$169.7M
Q1 24
$1.6B
$340.1M
Total Debt
BIO
BIO
BRKR
BRKR
Q4 25
$1.2B
$1.9B
Q3 25
$1.2B
$2.0B
Q2 25
$2.4B
Q1 25
$2.1B
Q4 24
$1.2B
$2.1B
Q3 24
$2.3B
Q2 24
$2.2B
Q1 24
$1.4B
Stockholders' Equity
BIO
BIO
BRKR
BRKR
Q4 25
$7.5B
$2.5B
Q3 25
$6.7B
$2.4B
Q2 25
$7.1B
$1.8B
Q1 25
$6.7B
$1.8B
Q4 24
$6.6B
$1.8B
Q3 24
$7.5B
$1.8B
Q2 24
$6.8B
$1.8B
Q1 24
$9.1B
$1.4B
Total Assets
BIO
BIO
BRKR
BRKR
Q4 25
$10.6B
$6.2B
Q3 25
$9.7B
$6.4B
Q2 25
$10.2B
$6.3B
Q1 25
$9.5B
$5.9B
Q4 24
$9.4B
$5.8B
Q3 24
$10.6B
$6.1B
Q2 24
$9.7B
$5.9B
Q1 24
$12.6B
$4.5B
Debt / Equity
BIO
BIO
BRKR
BRKR
Q4 25
0.16×
0.76×
Q3 25
0.18×
0.83×
Q2 25
1.34×
Q1 25
1.15×
Q4 24
0.18×
1.18×
Q3 24
1.27×
Q2 24
1.21×
Q1 24
0.97×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIO
BIO
BRKR
BRKR
Operating Cash FlowLast quarter
$164.9M
$229.8M
Free Cash FlowOCF − Capex
$119.1M
$207.2M
FCF MarginFCF / Revenue
17.2%
21.2%
Capex IntensityCapex / Revenue
6.6%
2.3%
Cash ConversionOCF / Net Profit
0.23×
8.84×
TTM Free Cash FlowTrailing 4 quarters
$374.6M
$43.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIO
BIO
BRKR
BRKR
Q4 25
$164.9M
$229.8M
Q3 25
$120.9M
$-33.2M
Q2 25
$116.5M
$-127.5M
Q1 25
$129.9M
$65.0M
Q4 24
$124.2M
$190.0M
Q3 24
$163.6M
$38.4M
Q2 24
$97.6M
$1.1M
Q1 24
$69.8M
$21.8M
Free Cash Flow
BIO
BIO
BRKR
BRKR
Q4 25
$119.1M
$207.2M
Q3 25
$89.2M
$-54.1M
Q2 25
$70.8M
$-148.8M
Q1 25
$95.5M
$39.0M
Q4 24
$81.2M
$153.3M
Q3 24
$123.4M
$5.8M
Q2 24
$55.4M
$-23.5M
Q1 24
$29.6M
$400.0K
FCF Margin
BIO
BIO
BRKR
BRKR
Q4 25
17.2%
21.2%
Q3 25
13.7%
-6.3%
Q2 25
10.9%
-18.7%
Q1 25
16.3%
4.9%
Q4 24
12.2%
15.6%
Q3 24
19.0%
0.7%
Q2 24
8.7%
-2.9%
Q1 24
4.8%
0.1%
Capex Intensity
BIO
BIO
BRKR
BRKR
Q4 25
6.6%
2.3%
Q3 25
4.9%
2.4%
Q2 25
7.0%
2.7%
Q1 25
5.9%
3.2%
Q4 24
6.4%
3.7%
Q3 24
6.2%
3.8%
Q2 24
6.6%
3.1%
Q1 24
6.6%
3.0%
Cash Conversion
BIO
BIO
BRKR
BRKR
Q4 25
0.23×
8.84×
Q3 25
Q2 25
0.37×
-16.78×
Q1 25
2.03×
3.74×
Q4 24
13.87×
Q3 24
0.25×
0.94×
Q2 24
0.14×
Q1 24
0.18×
0.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIO
BIO

Clinical Diagnostics$425.3M61%
Life Science$267.9M39%

BRKR
BRKR

Bsi Nano$309.1M32%
Bsi Biospin$267.0M27%
Other$179.9M18%
Transferred Over Time$142.5M15%
Energy And Supercon Technologies$69.5M7%

Related Comparisons